Form D · Biotechnology
Rubius Therapeutics, Inc.
Cambridge, MA · CIK 0001709401
Offering snapshot reported Mar 1, 2018 · SEC filing
- Reported sold
- $101M Offering amount: $101M
- Investors reported
- 27 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 23, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 1, 2018 | Initial | $101,200,005 | No comparison | 27 | SEC filing |
| Jun 22, 2017 | Initial | $115,000,060 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-306744
Amount sold shown in item 13 and number of investors shown in item 14 includes $20,199,963 from 6 non-US investors.
Source: Form D, filed Mar 1, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Noubar B. Afeyan | Director |
| Christopher L. Carpenter | Executive |
| Francis Cuss | Director |
| David Epstein | Director |
| Peter Barton Hutt | Director |
| Robert S. Langer | Director |
| Harvey F. Lodish | Director |
| Torben Straight Nissen | Director, Executive |
| Andrew Oh | Executive |
| Roger Pomerantz | Director |
| Joanne Protano | Executive |
| Michael Rosenblatt | Director |
| Catherine Sohn | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
325 Vassar Street, Suite 1 A
Cambridge, MA, 02139
Cambridge, MA, 02139